217 related articles for article (PubMed ID: 27017545)
21. Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.
Yang LL; Li GB; Yan HX; Sun QZ; Ma S; Ji P; Wang ZR; Feng S; Zou J; Yang SY
Eur J Med Chem; 2012 Oct; 56():30-8. PubMed ID: 22944772
[TBL] [Abstract][Full Text] [Related]
22. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
[TBL] [Abstract][Full Text] [Related]
23. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
[TBL] [Abstract][Full Text] [Related]
24. Structural basis for the design of bisubstrate inhibitors of protein kinase CK2 provided by complex structures with the substrate-competitive inhibitor heparin.
Schnitzler A; Niefind K
Eur J Med Chem; 2021 Mar; 214():113223. PubMed ID: 33571828
[TBL] [Abstract][Full Text] [Related]
25. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2.
Horiuchi T; Nagata M; Kitagawa M; Akahane K; Uoto K
Bioorg Med Chem; 2009 Dec; 17(23):7850-60. PubMed ID: 19889545
[TBL] [Abstract][Full Text] [Related]
26. Structure-activity relationship study of 4-(thiazol-5-yl)benzoic acid derivatives as potent protein kinase CK2 inhibitors.
Ohno H; Minamiguchi D; Nakamura S; Shu K; Okazaki S; Honda M; Misu R; Moriwaki H; Nakanishi S; Oishi S; Kinoshita T; Nakanishi I; Fujii N
Bioorg Med Chem; 2016 Mar; 24(5):1136-41. PubMed ID: 26850376
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel tricyclic pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine derivatives as VEGFR-2 inhibitors.
Abdel Aziz YM; Said MM; El Shihawy HA; Abouzid KA
Bioorg Chem; 2015 Jun; 60():1-12. PubMed ID: 25899678
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of new pyrimidine-4-yl-ethanol derivatives as ROS1 kinase inhibitors.
Abdelazem AZ; Lee SH
J Enzyme Inhib Med Chem; 2015 Apr; 30(2):290-8. PubMed ID: 24939104
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of novel 2 (4`-hydroxynaphthyl) chromen-4-one as a CK2 inhibitor.
Haidar S; Jabbour M; Al-Khayat MA; Aichele D; Jose J
Pharmazie; 2018 Apr; 73(4):191-195. PubMed ID: 29609684
[TBL] [Abstract][Full Text] [Related]
30. Design of 2-amino-6-methyl-pyrimidine benzoic acids as ATP competitive casein kinase-2 (CK2) inhibitors using structure- and fragment-based design, docking and molecular dynamic simulation studies.
Patel S; Patel S; Tulsian K; Kumar P; Vyas VK; Ghate M
SAR QSAR Environ Res; 2023 Mar; 34(3):211-230. PubMed ID: 37051759
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
[TBL] [Abstract][Full Text] [Related]
32. Discovery and characterization of synthetic 4'-hydroxyflavones-New CK2 inhibitors from flavone family.
Golub AG; Bdzhola VG; Ostrynska OV; Kyshenia IV; Sapelkin VM; Prykhod'ko AO; Kukharenko OP; Yarmoluk SM
Bioorg Med Chem; 2013 Nov; 21(21):6681-9. PubMed ID: 24011954
[TBL] [Abstract][Full Text] [Related]
33. Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines.
Alberti MJ; Auten EP; Lackey KE; McDonald OB; Wood ER; Preugschat F; Cutler GJ; Kane-Carson L; Liu W; Jung DK
Bioorg Med Chem Lett; 2005 Aug; 15(16):3778-81. PubMed ID: 15993060
[TBL] [Abstract][Full Text] [Related]
34. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S
Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
[TBL] [Abstract][Full Text] [Related]
36. Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.
Hundsdörfer C; Hemmerling HJ; Götz C; Totzke F; Bednarski P; Le Borgne M; Jose J
Bioorg Med Chem; 2012 Apr; 20(7):2282-9. PubMed ID: 22377675
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2.
Golub AG; Yakovenko OY; Prykhod'ko AO; Lukashov SS; Bdzhola VG; Yarmoluk SM
Biochim Biophys Acta; 2008 Jan; 1784(1):143-9. PubMed ID: 18021749
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
[TBL] [Abstract][Full Text] [Related]
39. Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors.
Miyazaki Y; Maeda Y; Sato H; Nakano M; Mellor GW
Bioorg Med Chem Lett; 2008 Mar; 18(6):1967-71. PubMed ID: 18280153
[TBL] [Abstract][Full Text] [Related]
40. Diversity-oriented synthesis of pyrazolo[4,3-b]indoles by gold-catalysed three-component annulation: application to the development of a new class of CK2 inhibitors.
Hou Z; Oishi S; Suzuki Y; Kure T; Nakanishi I; Hirasawa A; Tsujimoto G; Ohno H; Fujii N
Org Biomol Chem; 2013 May; 11(20):3288-96. PubMed ID: 23535832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
